[1] Tang A, Hallouch O, Chernyak Ⅴ, et al. Epidemiology of hepatocellular carcinoma: target population for surveillance and diagnosis[J]. Abdom Radiol (NY), 2018, 43(1):13-25.
[2] Akk?z H. Hepatocellular carcinoma: from molecular basis to novel treatment approaches[J]. Can J Gastroenterol Hepatol, 2019, 2019:4970731.
[3] Lin DC, Mayakonda A, Dinh HQ, et al. Genomic and epigenomic heterogeneity of hepatocellular carcinoma[J]. Cancer Res, 2017, 77(9):2255-2265.
[4] Lee SM, Kim-Ha J, Choi WY, et al. Interplay of genetic and epigenetic alterations in hepatocellular carcinoma[J]. Epigenomics, 2016, 8(7):993-1005.
[5] Rongrui L, Na H, Zongfang L, et al. Epigenetic mechanism involved in the HBV/HCV-related hepatocellular carcinoma tumorigenesis[J]. Curr Pharm Des, 2014, 20(11):1715-1725.
[6] Yu M, Luo H, Fan M, et al. Development of GPC3-specific chimeric antigen receptor-engineered natural killer cells for the treatment of hepatocellular carcinoma[J]. Mol Ther, 2018, 26(2):366-378.
[7] Cartier F, Indersie E, Lesjean S, et al. New tumor suppressor microRNAs target glypican-3 in human liver cancer[J]. Oncotarget, 2017, 8(25):41211-41226.
[8] Shimizu Y, Suzuki T, Yoshikawa T, et al. Nextgeneration cancer immunotherapy targeting glypican-3[J]. Front Oncol, 2019, 9:248.
[9] Nishida T, Kataoka H. Glypican 3-targeted therapy in hepatocellular carcinoma[J]. Cancers (Basel), 2019, 11(9):1339.
[10] Arendt BM, Teterina A, Pettinelli P, et al. Cancer-related gene expression is associated with disease severity and modifiable lifestyle factors in non-alcoholic fatty liver disease[J]. Nutrition, 2019, 62:100-107.
[11] Aichem A, Groettrup M. The ubiquitin-like modifier FAT10 in cancer development[J]. Int J Biochem Cell Biol, 2016, 79:451-461.
[12] Hernández M, Quijada NM, Rodríguez-Lázaro D, et al. Bioinformatics of next generation sequencing in clinical microbiology diagnosis [J]. Rev Argent Microbiol, 2020, 52(2):150-161.
[13] Keerthikumar S. An introduction to proteome bioinformatics [J]. Methods Mol Biol, 2017, 1549: 1-3.
[14] Li N, Gao W, Zhang YF, et al. Glypicans as cancer therapeutic targets[J]. Trends Cancer, 2018, 4(11):741-754.
[15] French SW, Bardag-Gorce F, French BA, et al. The role of innate immunity in the pathogenesis of preneoplasia in drug-induced chronic hepatitis based on a mouse model[J]. Exp Mol Pathol, 2011, 91(3):653-659.
[16] Filmus J, Capurro M, Rast J. Glypicans[J]. Genome Biol, 2008, 9(5):224.
[17] Wu M, Liu Z, Zhang A, et al. Associated measurement of fucosylated levels of AFP, DCP, and GPC3 for early diagnosis in hepatocellular carcinoma[J]. Int J Biol Markers, 2019, 34(1):20-26.
[18] Sun B, Huang Z, Wang B, et al. Significance of glypican-3 (GPC3) expression in hepatocellular cancer diagnosis[J]. Med Sci Monit, 2017, 23:850-855.
[19] Oliva J, Bardag-Gorce F, French BA, et al. Independent phenotype of binuclear hepatocytes and cellular localization of UbD[J]. Exp Mol Pathol, 2010, 89(2):103-108.
[20] Cui J, Chen Y, Wang HY, et al. Mechanisms and pathways of innate immune activation and regulation in health and cancer[J]. Hum Vaccin Immunother, 2014, 10(11):3270-3285.
|